Wechselwirkungen · Fotivda
Fotivda 890 microgram hard capsules Fotivda 1340 microgram hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-224258 · Präparat HOS-217292
Medicinal products for which intestinal absorption is restricted by BCRP Tivozanib inhibits the transporter protein BCRP in vitro, but the clinical relevance of this finding is unknown (see section 5.2). Caution should be exercised if tivozanib is co-administered with rosuvastatin. Alternatively, a statin not subject to restriction of intestinal absorption by BCRP should be considered. Patients taking an oral BCRP substrate with a clinically-relevant efflux interaction in the gut should ensure that a suitable time window (e.g. 2 hours) is applied between administration of tivozanib and the BCRP substrate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-07-17T18:03:00Z · SHA-256 5adff06e7a425b4fd92da57f9cd3701460fe08ddeba4b8206efbffdf9767d65a · Passage 0363b080148a459a2992e62fc16a367d05f5f487a69193391322521bcfedae2d · Zeichen 1681–2293 im Abschnitt